Soligenix, Inc. (SNGX)
0.3602
+0.01
(+2.88%)
USD |
NASDAQ |
Oct 22, 11:02
Soligenix Net Income (Quarterly) : -1.987M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.987M |
| March 31, 2026 | -2.825M |
| December 31, 2025 | -2.896M |
| September 30, 2025 | -2.531M |
| June 30, 2025 | -2.702M |
| March 31, 2025 | -2.951M |
| December 31, 2024 | -2.987M |
| September 30, 2024 | -1.719M |
| June 30, 2024 | -1.644M |
| March 31, 2024 | -1.915M |
| December 31, 2023 | -1.820M |
| September 30, 2023 | -1.663M |
| June 30, 2023 | -1.612M |
| March 31, 2023 | -1.046M |
| December 31, 2022 | -3.754M |
| September 30, 2022 | -3.309M |
| June 30, 2022 | -2.387M |
| March 31, 2022 | -4.349M |
| December 31, 2021 | -4.704M |
| September 30, 2021 | -3.588M |
| June 30, 2021 | -1.897M |
| March 31, 2021 | -2.362M |
| December 31, 2020 | -5.540M |
| September 30, 2020 | -1.790M |
| June 30, 2020 | -2.777M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.581M |
| December 31, 2019 | -2.872M |
| September 30, 2019 | -2.721M |
| June 30, 2019 | -2.124M |
| March 31, 2019 | -1.640M |
| December 31, 2018 | -3.105M |
| September 30, 2018 | -1.862M |
| June 30, 2018 | -1.556M |
| March 31, 2018 | -2.377M |
| December 31, 2017 | -2.139M |
| September 30, 2017 | -0.9631M |
| June 30, 2017 | -2.312M |
| March 31, 2017 | -1.733M |
| December 31, 2016 | -0.33M |
| September 30, 2016 | -1.673M |
| June 30, 2016 | -0.0928M |
| March 31, 2016 | -1.149M |
| December 31, 2015 | -2.059M |
| September 30, 2015 | 2.774M |
| June 30, 2015 | -3.978M |
| March 31, 2015 | -4.569M |
| December 31, 2014 | 1.923M |
| September 30, 2014 | -4.350M |
| June 30, 2014 | -0.9485M |
| March 31, 2014 | -3.332M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.987M |
| EPS Diluted (Quarterly) | -0.1246 |
| Enterprise Value | -1.933M |
| Earnings Yield | -353.8% |
| Normalized Earnings Yield | -354.47 |